Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nextcure Inc (NQ: NXTC )

1.220 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.220
Bid (Size) 1.200 (3)
Ask (Size) 1.350 (3)
Prev. Close 1.220
Today's Range 1.220 - 1.220
52wk Range 0.9800 - 1.910
Shares Outstanding 27,903,027
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference
From NextCure
Via GlobeNewswire
NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML
From NextCure
Via GlobeNewswire

Performance

YTD
-18.12%
-18.12%
1 Month
+9.91%
+9.91%
3 Month
-17.57%
-17.57%
6 Month
-26.95%
-26.95%
1 Year
-11.59%
-11.59%

More News

Read More
NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results
From NextCure
Via GlobeNewswire
NextCure, LegoChem Biosciences Ink Collaborative Pact For Antibody Drug Conjugates
Via Benzinga
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)
From NextCure
Via GlobeNewswire
NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer’s Disease
From NextCure
Via GlobeNewswire
A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC
From NextCure
Via GlobeNewswire
NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagen
From NextCure
Via GlobeNewswire
Preclinical Data Demonstrate Potential Application of Anti-Siglec-15 Treatment in Bone Disease
From NextCure
Via GlobeNewswire
NextCure to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From NextCure
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2023
Via Benzinga
NextCure Provides Business Update and Reports Second Quarter 2023 Financial Results
From NextCure
Via GlobeNewswire
NextCure Presents Non-Clinical Data Defining the Mechanism of NC525 at the 2023 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting
From NextCure
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
NextCure to Present at the JMP Securities Life Sciences Conference
From NextCure
Via GlobeNewswire
NextCure Provides Business Update and Reports First Quarter 2023 Financial Results
From NextCure
Via GlobeNewswire
NextCure to Present at 22nd Annual Needham Virtual Healthcare Conference
From NextCure
Via GlobeNewswire
NextCure Provides Business Update and Reports Full Year 2022 Financial Results
From NextCure
Via GlobeNewswire
NextCure to Present at SVB Securities Global Biopharma Conference
From NextCure
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
NextCure to Present at Upcoming Investor Conferences
From NextCure
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
NextCure and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody Drug Conjugates
From NextCure
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.